Our Story

Jotbody is an early-stage biotechnology company founded in 2020 with dual sites operating in Hong Kong and Shenzhen, China. We can count on an excellent network of entrepreneurs and experienced scientists with a strong background in biochemistry, immunology and drug delivery.

We are dedicated to providing researchers with Single Domain Antibody of out-standing quality for in vitro diagnosis and therapy.

Jotbody是一家處於早期發展階段的生物技術公司,在中國香港和深圳都設有分公司。我們依靠一個優秀的企業家網路以及在生物化學、免疫學和藥物傳遞領域具有強大研究背景的科學家。我們致力於為研究人員提供高品質的納米抗體用於科學研究、體外診斷和臨床治療

Our Goal

We aim to speed up research and discovery by providing the highest quality Single Domain Antibody at an outstanding value and with excellent customer and technical support.

我們的目標是通過提供高品質的納米抗體,以卓越的客戶和技術支援,加快納米抗體的研究和發展

Our Mission

We envision a World where high-quality R&D can be broadly accessed and can generate significant benefit for patients and healthcare payers worldwide.

我們的使命是,高品質的研發可以被全世界生物醫藥健康從業者廣泛獲取,並可以為全人類帶來重大利益。

Our Vision

Single domain antibody holds the potential to revolutionizing many aspects of the actual clinical settings. We want to contribute to the development of a new wave of therapeutics.

納米抗體具有很大的潛力革新目前許多實際臨床應用場景。我們希望為新一波治療學的發展做出貢獻。


Collaborate with Us

We constantly scout opportunities that have innovative potential to solve unmet needs. If you believe that your product fits within our scope, we are open to collaborate with you. Please contact us for more information.
We look forward to developing a mutually beneficial collaboration with you.

我們不斷尋找有創新潛力的機會,以解決未被滿足的需求。如果您認為您的產品符合我們的經營範圍,我們願意與您合作。請聯繫我們瞭解更多資訊

我們期待與您發展互惠互利的合作關係

Our Key Partners

我們的主要合作夥伴

To provide an high quality service, it is very important to share knowledge and work with accreditated partners. Jotbody has established partnerships with different Biotechnology Companies , Research Institutes and Universities including:

為提供高品質的服務,與認可的合作夥伴分享知識和合作是非常重要的。Jotbody與不同的生物技術公司、研究機構和大學建立了合作夥伴關係,包括:

Innovation

Patents:

  • High-affinity anti-EGFP and anti-SARS-CoV-2 vNAR single domain antibodies and use thereof. PCT/CN2021/128297
  • Method of Producing Antibody Fragment, CN201811318557.4
  • Specific primer pairs designed for single variable new antigen receptor domain derived from IgNAR of Chiloscyllium plagiosum, CN111197074A
  • Method of Producing Antibody Fragment, US20190135904

創新

Selected publications:

出版物

  • Bamboo sharks for affordable single domain antibody production. Front. Bioeng. Biotechnol. 9:792111
  • Cas9-based local enrichment and genomics sequence revision of megabase-size shark immunoglobulin new antigen receptor loci. J Immunol. 2022 Jan 1;208(1):181-189
  • Covalent conjugation of extracellular vesicles with peptides and nanobodies for targeted therapeutic delivery. J ExtracellVesicles. 2021;10:e12057
  •  The White-Spotted Bamboo Shark Genome Reveals Chromosome Rearrangements and Fast-Evolving Immune Genes of Cartilaginous Fish. Iscience. 2020; 23(11): 101754
  • The novel llama-human chimeric antibody has potent effect in lowering LDL-c levels in hPCSK9 transgenic rats. Clin Trans Med. 2020;09, 16

Awards

獎項

  • Awardee HK Tech 300 Angel Fund (2022)
  • Incubatee of HKSTP Incu-Bio Programme (2021)
  • Incubatee of Shenzhen Engineering Biology Industry Innovation Center (2021)
  • Awardee of HK Teck 300 seed fund (2021)
  • The 13th China (Shenzhen) Innovation and Entrepreneurship Competition, Shenzhen-Hong Kong-Macao University Preliminary Competition, Winning Prize (2021)
  • The 4th China (Guangdong) Chuangyi Innovation and Entrepreneurship Preliminary Competition, Silver Award (2021)

Let’s make something together.

讓我們一起做點什麼吧